APA (7th ed.) Citation

Sim, S. H., Kim, J. E., Kim, M. H., Park, Y. H., Kim, J. H., Suh, K. J., . . . Park, I. H. (2022). Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B). Elsevier.

Chicago Style (17th ed.) Citation

Sim, Sung Hoon, et al. Phase II Study to Investigate the Efficacy of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients with Heavily Pretreated HER-2+ Metastatic Breast Cancer (KCSG BR 18–14/KM10B). Elsevier, 2022.

MLA (9th ed.) Citation

Sim, Sung Hoon, et al. Phase II Study to Investigate the Efficacy of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients with Heavily Pretreated HER-2+ Metastatic Breast Cancer (KCSG BR 18–14/KM10B). Elsevier, 2022.